LifeTech Capital Updates Echo Therapeutics With Strong Speculative Buy, $6 PT

LifeTech Capital updated its Echo Therapeutics

rating and price target with a Strong Speculative Buy and $6 price target in a research report published today. In the report, LifeTech Capital states, "Echo Therapeutics has moved their Headquarters to Philadelphia and they have added a new CFO, a new VP of Operations, a new VP of Research and 2 additional independent directors to the Board of Directors as they prepare for a national listing on the NASDAQ or the AMEX stock exchanges while simultaneously preparing for the launch of the Prelude(TM) skin prep system while continuing the clinical development of the Symphony(TM) tGCM System." Shares of Echo Therapeutics were trading at $3.97 at the time of posting, down 6.15% from Friday's market close.